Trial
NCT02534038
Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
—
Condition
Disinhibition Syndrome
Intervention
AVP-786
Why stopped
The study was terminated prematurely because of difficulty with recruiting.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-13